Evidence map›Paper›PMID 42147335›Full record

ArticleFrontiers in pharmacology2026

Tat-HSPE1 suppresses clear cell renal cell carcinoma growth through lysosome-dependent cell death.

Lin Zhang, Weiyuan Li, Min Liu, Dong Li, Guang-Zhi Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lin Zhang *Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiyuan Li *Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Min LiuDepartment of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dong LiDepartment of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Guang-Zhi JinDepartment of Pathology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer; however, first-line therapeutic agents show limited efficacy in patients with advanced disease. Bioactive peptides have emerged as promising candidates for anticancer therapy. In this study, a novel peptide derived from Heat Shock Protein Family E Member 1 (HSPE1) was identified by peptidomics analysis of human ccRCC tissues and paired adjacent normal tissues. We then engineered a novel fusion peptide designated Tat-HSPE1. Tat-HSPE1 selectively induced

Indexed as

autophagyCTTNBP2NLheat shock proteinslysosomal membrane permeabilization (lmp)peptiderenal cancer

Identifiers

PMID42147335
PMCPMC13176256

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.